Planned follow-up studies include in vivo efficacy and toxicity assessments (murine xenograft models for prostate cancer and leukemia) and pathway-specific assays to delineate the mechanisms underlying NF-κB suppression. This evidence concerns the gene NFKB1 and prostate carcinoma.